M. Menefee

发表

Foundation OneTM Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy.

R. Smallridge, John C. Morris, K. Bible, 2020, The Journal of clinical endocrinology and metabolism.

Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

E. Plimack, P. LoRusso, J. Rosenberg, 2014, Clinical Cancer Research.

Anaplastic Thyroid Cancer

R. Smallridge, J. Casler, M. Menefee, 2018 .

Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.

T. Fojo, M. Menefee, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies

Erin L. Schenk, C. Erlichman, D. Northfelt, 2013, Investigational New Drugs.

Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).

A. Fojo, M. Menefee, 2005, Seminars in oncology.

The efficacy of combination chemotherapy with cisplatin and gemcitabine in patients with advanced adrenal cortical carcinoma (ACC).

A. Fojo, M. Edgerly, M. Menefee, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Jesse S. Voss, B. Goh, R. Smallridge, 2020, Thyroid : official journal of the American Thyroid Association.

Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

C. Erlichman, K. Bible, S. Ivy, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract B56: A phase I trial of the combination of dasatinib and lapatinib

M. Borad, C. Erlichman, D. Northfelt, 2009 .

CLO19-026: Determining the Treatment Decision of Tumors With Mixed Response

J. Copland, Candice Baldeo, T. Kaleem, 2019, Journal of the National Comprehensive Cancer Network.

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

Andrea K. Kukla, B. Goh, R. Smallridge, 2012, The Journal of clinical endocrinology and metabolism.

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma

T. Fojo, S. Bates, M. Poruchynsky, 2010, Clinical Cancer Research.

Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers

E. Perez, J. Copland, L. Marlow, 2012, Molecular Cancer Therapeutics.

Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma

S. Bates, J. Yang, W. Stein, 2009, Cancer journal.

A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer.

W. Linehan, T. Fojo, S. Bates, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSC 710428 ) , an Epothilone B Analog , in Patients with Metastatic Renal Cell Carcinoma

T. Fojo, S. Bates, M. Poruchynsky, 2010 .

Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma.

J. Copland, L. Marlow, G. T. Kennedy, 2013, American journal of cancer research.

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

J. Wright, S. Geyer, M. Shah, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

Erin L. Schenk, B. Costello, L. Doyle, 2021, Investigational New Drugs.

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

D. Gandara, C. Erlichman, A. Adjei, 2019, Investigational New Drugs.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

R. Smallridge, C. Erlichman, V. Suman, 2014, The Journal of clinical endocrinology and metabolism.

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Y. Houvras, M. Heckman, J. Copland, 2013, The Journal of clinical endocrinology and metabolism.

A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells

S. Bates, M. Merino, A. Fojo, 2005 .

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

B. Goh, R. Smallridge, Hui Tang, 2010, The Lancet. Oncology.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

L. Hartmann, F. Boakye-Agyeman, A. Chen, 2017, Clinical Cancer Research.

Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.

R. Smallridge, C. Erlichman, V. Suman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MEDI-573 as a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase I PK/PD, safety data, and disease linkage studies in breast cancer.

P. Haluska, Jiaqi Huang, Yihong Yao, 2011, Journal of Clinical Oncology.

Phase I trial of dasatinib (D) and lapatinib (L).

R. Marks, C. Erlichman, D. Northfelt, 2010 .

Mixed response to immunotherapy in lung cancer.

J. Copland, Candice Baldeo, T. Kaleem, 2019, Journal of Clinical Oncology.